We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Announces Clinical Milestone within Boehringer Ingelheim Alliance
News

MorphoSys Announces Clinical Milestone within Boehringer Ingelheim Alliance

MorphoSys Announces Clinical Milestone within Boehringer Ingelheim Alliance
News

MorphoSys Announces Clinical Milestone within Boehringer Ingelheim Alliance

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Announces Clinical Milestone within Boehringer Ingelheim Alliance"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that it has received a clinical milestone payment from Boehringer Ingelheim in connection with the regulatory filing of a clinical trial application for a phase 1 trial of a HuCAL-derived antibody. The filing took place in late December 2010 making this the eighth clinical milestone met with partners during the year. Financial details are not disclosed.

"In 2010, we saw eight clinical milestones reached with five different partners which surpassed our original expectations for the year of up to six such events," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news marks the start of the first clinical program within our partnership with Boehringer Ingelheim."

MorphoSys's clinical pipeline now comprises ten partnered programs in Phase 1 and five in Phase 2 development as well as the Company's proprietary programs MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and MOR208, which is in a Phase 1 trial for chronic lymphocytic leukemia.

Advertisement